Abbott Cancerguard Test Delivers 47.1% Methylation, 7.4% Protein Detection
Abbott’s new AACR data show its Cancerguard test uses methylation-only (47.1%), protein-only (7.4%) and combined biomarker signals (45.5%) to enhance early cancer detection with just 2.6% false positives. DETECT-A follow-up revealed 100% survival for nine stage I/II cancers after four years.
1. AACR Data Demonstrate Multi-Biomarker Performance
At the AACR 2026 meeting, Abbott highlighted how its Cancerguard test integrates methylation and protein biomarkers to detect cancer across stages. In a prospective case-control study, methylation-only signals accounted for 47.1% of positives, protein-only for 7.4% and combined signals for 45.5%, yielding just 2.6% false positives.
2. DETECT-A Long-Term Outcomes Highlight Clinical Impact
Abbott celebrated the DETECT-A study’s four-year follow-up showing 100% survival in nine early-stage cancers, including types without standard screening. These multiyear outcomes support the clinical utility of multi-cancer early detection and bolster the case for broader adoption of the Cancerguard test.